Full Coverage

NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study

                   
marketwire.com
May 28, 2008
        
Story Timeline:  191 days

SOPHIA ANTIPOLIS, FRANCE--(Marketwire - May 28, 2008) - May 28, 2008. Sophia Antipolis, France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the completion of patient enrollment in the third pivotal phase 3 clinical trial for naproxcinod, in patients with osteoarthritis of the... [read full story]                    

Add Comment
Latest article on this story:

NicOx Completes Patient Enrollment In Third Naproxcinod Pivotal Phase 3 Study

 medicalnewstoday.com May 29, 2008
First article on this story:

NICOX: NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study

 marketwire.com May 28, 2008
Selected publications with coverage of this story:
redorbit.com easybourse.com prnewswire.com marketwatch.com marketwire.com medicalnewstoday.com yahoo.com newsblaze.com
RELATED
Found 8 documents:
                   

NicOx Completes Patient Enrollment In Third Naproxcinod Pivotal Phase 3 Study

medicalnewstoday.com
May 29, 2008
        

NicOx S.A. (Euronext Paris: COX) announced the completion of patient enrollment in the third pivotal phase 3 clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study). 810 patients have been randomized in 120 clinical centers in North America and Europe in this...

                   

NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study

prnewswire.com
May 28, 2008
        

NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study SOPHIA ANTIPOLIS, France, May 28 /PRNewswire-FirstCall/ -- 810 patients have been randomized in 120 clinical centers in North America and Europe in this study, which is the final phase 3 trial in NicOx' clinical plan...

NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study (Marketwire)

yahoo.com
May 28, 2008
        

Wednesday May 28, 1:00 am ET SOPHIA ANTIPOLIS, FRANCE--(MARKET WIRE)--May 28, 2008 -- 810 patients have been randomized in 120 clinical centers in North America and Europe in this study , which is the final phase 3 trial in NicOx' clinical plan for the regulatory filing of naproxcinod. The...

                   

NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study

redorbit.com
May 28, 2008
        

May 28, 2008. Sophia Antipolis, France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the completion of patient enrollment in the third pivotal phase 3 clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study).

                   

NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study

easybourse.com
May 28, 2008
        

Sophia Antipolis, France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the completion of patient enrollment in the third pivotal phase 3 clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study). 810 patients have been randomized in 120 clinical...

                   

NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study

newsblaze.com
May 28, 2008
        

Sophia Antipolis, France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the completion of patient enrollment in the third pivotal phase 3 clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study). 810 patients have been randomized in 120 clinical...

NicOx enrolls patients for final Phase III test of a drug

marketwatch.com
May 28, 2008
        

TEL aVIV (MarketWatch) -- NicOx SA, the Sophia Antipolis, France, drugmaker, completed patient enrollment for the final Phase III clinical trial of naproxcinod for patients with osteoarthritis of the hip. NicOx has randomized 810 patients at 120 clinical centers in North America and Europe for...

                   

NICOX: NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study

marketwire.com
May 28, 2008
        

SOPHIA ANTIPOLIS, FRANCE--(Marketwire - 810 patients have been randomized in 120 clinical centers in North America and Europe in this study , which is the final phase 3 trial in NicOx' clinical plan for the regulatory filing of naproxcinod. Results from this study are expected in Q4, 2008 and...